Navigating the commercial landscape for high-purity research compounds requires an understanding of synthesis standards, analytical validation, and unit valuation. Research-grade CJC-1295 DAC prices typically range between $45 and $90 per 2mg to 5mg vial, with pricing dictated primarily by HPLC purity verification, endotoxin testing standards, and US-based manufacturing protocols.
Navigating the commercial landscape for high-purity research compounds requires an understanding of synthesis standards, analytical validation, and unit valuation. Research-grade CJC-1295 DAC prices typically range between $45 and $90 per 2mg to 5mg vial, with pricing dictated primarily by HPLC purity verification, endotoxin testing standards, and US-based manufacturing protocols.
In the scientific supply market, cjc-1295 dac prices reflect the rigorous chemical synthesis and multi-stage purification protocols required to attach the Drug Affinity Complex (DAC) moiety to the native growth hormone-releasing hormone (GHRH) sequence. For verified research facilities, standard catalog pricing generally lands between $40.00 and $85.00 per 2mg to 5mg lyophilized vial. Institutional buyers seeking bulk procurement often see tiered per-unit reductions through dedicated wholesale laboratory accounts.
Price variations across vendors are rarely arbitrary; they directly correlate with analytical validation. Lower-cost alternatives frequently omit comprehensive mass spectrometry (MS) or High-Performance Liquid Chromatography (HPLC) batch testing, or fail to assess bacterial endotoxin levels. Investing in fully verified, US-manufactured peptides from an ISO 17025 accredited laboratory ensures that experimental variables remain tightly controlled across longitudinal animal and cell-culture studies.
CJC-1295 with DAC is a synthetic 29-amino acid peptide derivative of growth hormone-releasing hormone (GHRH 1-29). The defining structural characteristic of this compound is the addition of a lysine residue attached to a maleimidopropionic acid reactive group, collectively known as the Drug Affinity Complex. This specific modification allows the peptide to covalently bind to circulating serum albumin following administration in vivo.
In preclinical animal models, native GHRH exhibits a rapid clearance profile, possessing an elimination half-life measured in minutes due to rapid enzymatic degradation by dipeptidyl peptidase-IV (DPP-IV). By bioconjugating to endogenous albumin, the CJC-1295 DAC research peptide escapes immediate renal clearance and enzymatic cleavage, extending its biological half-life to approximately 6 to 8 days in rodent models. This prolonged stability fundamentally alters its pharmacokinetic evaluation compared to un-complexed peptides.
Evaluating cjc-1295 dac prices requires analyzing the cost structures involved in modern solid-phase peptide synthesis (SPPS). Producing a modified 29-amino acid sequence with a specific reactive chemical group demands specialized reagents, precise cleavage protocols, and repetitive purification cycles to eliminate truncated sequence artifacts.
The primary cost drivers in high-tier laboratory manufacturing include:
1. Reverse-Phase HPLC Purification: Achieving ≥98% purity requires repeated preparative chromatography runs, which consume significant solvent volumes and high-grade stationary phase media.
2. Mass Spectrometry Validation: Confirming exact molecular weight and identifying trace impurities via LC-MS instrumentation ensures lot-to-lot consistency.
3. Endotoxin Quantitation: For in vivo rodent research, low-endotoxin thresholds (<0.01 EU/µg) are required to prevent systemic inflammatory responses that distort research outcomes. LAL assay validation adds necessary quality assurance overhead.
4. Domestic cGMP Facilities: Synthesis within US-based, GMP-compliant facilities ensures adherence to ambient environmental controls, sterile handling, and total lot traceability.
When evaluating expenditure for growth hormone secretagogue protocols, researchers frequently compare CJC-1295 DAC against non-complexed GHRH analogs and growth hormone secretagogue receptor (GHSR) agonists. The choice of compound dramatically impacts both operational budgets and physiological modeling parameters.
For instance, CJC-1295 No DAC (often designated as modified GRF 1-29) lacks the albumin-binding linker. Consequently, it requires significantly more frequent dosing schedules in preclinical animal research to maintain active receptor occupancy, elevating total material consumption over extended research timelines. Similarly, first-generation analogs like Sermorelin present a shorter half-life requiring distinct handling protocols.
Conversely, highly targeted analogs like Tesamorelin offer distinct structural features optimized for specific lipodystrophy models. When constructing comprehensive research protocols, investigators often review comparative data across our growth hormone secretagogues guide to evaluate target affinity, half-life parameters, and cumulative procurement costs across different experimental models.
In vitro signaling assays and animal studies indicate that CJC-1295 DAC acts as a selective agonist at the growth hormone-releasing hormone receptor (GHRHR) located on pituitary somatotropes. Upon receptor binding, it stimulates the intracellular cAMP/protein kinase A (PKA) pathway, facilitating the transcription and exocytosis of endogenous growth hormone (GH).
Unlike short-acting secretagogues that induce acute, transient GH spikes, preclinical models demonstrate that CJC-1295 DAC sustains elevated baseline GH concentrations while preserving the natural pulsatile pattern of secretion. This continuous stimulation drives the downstream hepatic synthesis and secretion of Insulin-like Growth Factor 1 (IGF-1). In rodent models evaluating tissue repair, sustained IGF-1 elevation has been observed to support cellular proliferation, extracellular matrix remodeling, and nitrogen retention over multi-week experimental windows.
Purchasing decisions based solely on the lowest cjc-1295 dac prices often expose laboratories to compromised raw materials, sub-caliber purity, or heavy metal contamination. To maintain experimental integrity, institutional buyers must rigorously evaluate the Certificate of Analysis (COA) provided with each specific production lot.
A valid, third-party COA must originate from an independent ISO 17025 accredited analytical laboratory and feature clear RP-HPLC chromatograms showing peak area integration, mass spectrum graphs matching the theoretical molecular weight of CJC-1295 DAC (typically ~3647.95 Da), and specific quantitative values for residual solvents and endotoxin units. Generic or internal vendor COAs lacking lot traceability should be rejected.
To preserve structural integrity and prevent premature hydrolysis or aggregation of CJC-1295 DAC, strict reconstitution procedures must be observed in the laboratory environment. Lyophilized vials should be brought to room temperature prior to reconstitution to minimize moisture condensation within the container.
Reconstitution should be performed using laboratory-grade Bacteriostatic Water (0.9% benzyl alcohol) or sterile physiological saline, depending on the requirements of the planned assay. The solvent should be directed down the glass wall of the vial rather than sprayed directly onto the peptide cake. Gentle swirl agitation is recommended; violent shaking must be avoided as shear force can denature the peptide structure. Reconstituted solutions should be aliquoted and stored at -20°C or -80°C for long-term stability, avoiding repeated freeze-thaw cycles.
For academic institutions, biotechnology research firms, and contract research organizations (CROs), balancing procurement constraints with analytical rigor is essential. Sourcing high-purity GHRH analogs in volume allows research directors to secure consistent lot numbers, mitigating baseline experimental variances across long-term studies.
PX1 Research provides fully transparent supply chains for laboratory research use only. By controlling domestic US manufacturing, providing lot-specific HPLC/MS verification, and offering dedicated institutional account structures, laboratories can optimize their procurement budgets while maintaining uncompromising standards for preclinical assay reliability. Explore our full range of research compounds in the PX1 research peptide catalog.
What factors account for variations in CJC-1295 DAC prices between suppliers?
CJC-1295 DAC prices vary based on synthesis location (US vs. overseas), analytical testing rigor (third-party RP-HPLC, LC-MS, and endotoxin assays), facility standards (cGMP compliance), and purity thresholds (≥98% vs. unverified technical grade).
What is the structural difference between CJC-1295 DAC and CJC-1295 No DAC?
CJC-1295 DAC includes a Drug Affinity Complex (a maleimidopropionic acid linker) attached to a lysine residue, allowing it to covalently bind to serum albumin in vivo and extend its half-life to several days. CJC-1295 No DAC lacks this linker and has a half-life of approximately 30 minutes in rodent models.
What purity level is required for preclinical CJC-1295 DAC research?
Preclinical in vitro and in vivo studies generally require a minimum peptide purity of 98% as determined by RP-HPLC, alongside verified low endotoxin levels (<0.01 EU/µg) to prevent cellular toxicity or non-specific inflammatory responses.
How should lyophilized CJC-1295 DAC be stored upon delivery?
Unreconstituted, lyophilized CJC-1295 DAC should be stored in a desiccated environment at -20°C for short-term preservation or -80°C for long-term storage to prevent peptide degradation and moisture accumulation.
Why is endotoxin testing critical when purchasing research peptides?
Bacterial endotoxins (lipopolysaccharides) can trigger acute immune responses in animal models and alter gene expression in cell cultures. Ensuring low endotoxin levels is essential to isolate the specific physiological effects of the peptide.
How long does reconstituted CJC-1295 DAC remain stable in the laboratory?
Once reconstituted with bacteriostatic water, CJC-1295 DAC solutions remain stable at 2°C to 8°C for approximately 21 to 28 days. For extended timelines, solutions should be divided into single-use aliquots and frozen at -80°C.
How does CJC-1295 DAC compare to Sermorelin in terms of receptor binding?
Both CJC-1295 DAC and Sermorelin bind to and activate the GHRH receptor. However, Sermorelin corresponds to the unmodified 1-29 sequence and is rapidly cleared, whereas CJC-1295 DAC features substituted amino acids and the DAC moiety for extended receptor engagement.
Can institutions request lot-specific COAs before purchasing CJC-1295 DAC?
Yes. Reputable research suppliers like PX1 Research provide accessible, lot-specific Certificates of Analysis featuring HPLC and mass spectrometry data for every production batch prior to order fulfillment.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.